A
Alison Richards
Researcher at Flinders Medical Centre
Publications - 9
Citations - 114
Alison Richards is an academic researcher from Flinders Medical Centre. The author has contributed to research in topics: Cancer & Population. The author has an hindex of 5, co-authored 8 publications receiving 102 citations.
Papers
More filters
Journal ArticleDOI
A population-based study of metastatic colorectal cancer in individuals aged ≥ 80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer.
Rajesh Kumar,Kunal S. Jain,Carol Beeke,Timothy J. Price,Amanda R. Townsend,Robert Padbury,David Roder,Graeme P. Young,Alison Richards,Christos S. Karapetis +9 more
TL;DR: Optimal management for this group of patients with cancer at an advanced age has not been well defined.
Journal ArticleDOI
Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years.
Sunita Padman,Jaein Lee,Rajiv Kumar,Mark Slee,Paul Hakendorf,Paul Hakendorf,Alison Richards,Bogda Koczwara,Bogda Koczwara,Ganessan Kichenadasse,Ganessan Kichenadasse,Shawgi Sukumaran,Shawgi Sukumaran,Amitesh Roy,Amitesh Roy,Sina Vatandoust,Christos S. Karapetis,Christos S. Karapetis +17 more
TL;DR: Qualitative analysis demonstrated variable bio-psycho-social effects of chronic neuropathy but, importantly, highlighted that many patients felt they had been insufficiently warned of the risk of neuropathy.
Journal ArticleDOI
Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study
Janet K. Coller,Imogen A. White,Richard M. Logan,Jonathan Tuke,Alison Richards,Kelly R. Mead,Christos S. Karapetis,Christos S. Karapetis,Joanne M. Bowen +8 more
TL;DR: This is the first report of immune genetic variability, together with cancer type, being predictive of severe CIGT risk, and these outcomes are being validated in a larger patient population.
Journal ArticleDOI
Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up
M. Nazim Abbas,Adeola Ayoola,Sunita Padman,Rajiv Kumar,John Leung,Shahid Ullah,Bogda Koczwara,Bogda Koczwara,Shawgi Sukumaran,Shawgi Sukumaran,Ganessan Kichenadasse,Ganessan Kichenadasse,Amitesh Roy,Amitesh Roy,Alison Richards,Jeffrey Bowden,Christos S. Karapetis,Christos S. Karapetis +17 more
TL;DR: The 5-year OS of patients with stage III NSCLC treated with CRT was in keeping with survival figures reported from prospective clinical trials, there is, however, significant morbidity associated with long-term survival and this should be taken into account when making informed treatment decisions.
Journal ArticleDOI
Patient preferences on the integration of complementary therapy with conventional cancer care
Peter Savas,Amanda Robertson,Lisa Beatty,Emily Hookings,Margaret A. McGee,Julie Marker,Belle McCaleb,Joanne M. Bowen,Alison Richards,Bogda Koczwara +9 more
TL;DR: This study explored patient preferences regarding integration in an Australian context and found that complementary therapy use by patients with cancer is highly prevalent, although little is known about the optimal model of integration with conventional care.